Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators have placed ...

The obesity drug development pipeline is vast and includes both incretin ... with longer duration of action such as Eli Lilly ...

The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...

Amgen said Tuesday that the Food and Drug Administration has ordered a hold on a study of the company’s early-stage obesity candidate ... s later-stage candidate, MariTide, a monthly injectable ...

Investors were keenly interested to hear an update on Amgen’s obesity drug candidates, AMG-513 and MariTide. As noted above, the FDA has put AMG-513 on a clinical hold. Amgen says that it’s in ...

MariTide Phase 3 studies to begin in first half of year FDA places hold on AMG 513 obesity drug trial Amgen's Q4 earnings beat estimates, revenue up 11% Feb 4 (Reuters) - Amgen (AMGN.O), opens new ...

(Reuters) - Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators ...